Hydroxysafflor yellow A attenuates left ventricular remodeling after pressure overload-induced cardiac hypertrophy in rats

Pharmaceutical Biology

Volumn 52, Issue 1, 2014, Pages 31-35

  Wang, Jianping ^a   Zhang, Qing ^a   Mei, Xiuhua ^a   Zhang, Xiuzhen ^a  

^a YANTAI YUHUANGDING HOSPITAL   (China)

Author keywords

Anti apoptosis; Hydroxysafflor Yellow A; Left cardiac remodeling; Left ventricular remodeling; Metalloproteinases

Indexed keywords

CAPTOPRIL; CARDIOVASCULAR AGENT; GELATINASE A; GELATINASE B; HYDROXYSAFFLOR YELLOW A; PROTEIN BAX; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BODY MASS; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE CELL; IMMUNOHISTOCHEMISTRY; LEFT VENTRICULAR MASS INDEX; MALE; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RAT;

ANIMALS; APOPTOSIS; CAPTOPRIL; CARDIOMEGALY; CARTHAMUS TINCTORIUS; CHALCONE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; HYPERTENSION; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MEDICINE, CHINESE TRADITIONAL; MYOCYTES, CARDIAC; QUINONES; RATS; RATS, WISTAR; VENTRICULAR REMODELING;

EID: 84890500711     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.3109/13880209.2013.805791     Document Type: Article

References (23)

1. Chancey AL, Brower GL, Peterson JT, et al. (2002). Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation 105:1983-8
2. Choi YH, Cowan DB, Moran AM, et al. (2009). Myocyte apoptosis occurs early during the development of pressure-overload hypertrophy in infant myocardium. J Thorac Cardiovasc Surg 137: 1356-62
3. Condorelli G, Morisco C, Stassi G, et al. (1999). Increased cardiomyocyte apoptosis and changes in proapoptotic and antiapoptotic genes bax and bcl-2 during left ventricular adaptations to chronic pressure overload in the rat. Circulation 99:3071-8
4. Creemers EE, Cleutjens JP, Smits JF, et al. (2001). Matrix metalloproteinase inhibition after myocardial infarction: A new approach to prevent heart failure? Circ Res 89:201-10
5. Derosa G, D'Angelo A, Ciccarelli L, et al. (2006). Matrix metalloproteinase- 2,-9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium 13:227-31
6. Kim HE, Dalal SS, Young E, et al. (2000). Disruption of the myocardial extracellular matrix leads to cardiac dysfunction. J Clin Invest 106: 857-66
7. Koren MJ, Devereux RB, Casale PN, et al. (1991). Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Inter Med 114:345-52
8. Li S, Zhang Z, Wu L, et al. (2007). Understanding ZHENG in traditional Chinese medicine in the context of neuro-endocrineimmune network. IET Sys Biol 1:51-60
9. Liu ZF, Li CM, Li M, et al. (2004). The subchronic toxicity of hydroxysafflor yellow A of 90 days repeatedly intraperitoneal injections in rats. Toxicology 203:139-43
10. Liu S, Pereira NA, Teo JJ, et al. (2007). Mitochondrially targeted Bcl-2 and Bcl-X(L) chimeras elicit different apoptotic responses. Mol Cells 24:378-87
11. Pearson AC, Pasierski T, Labovitz AJ. (1991). Left ventricular hypertrophy: Prognosis and management. Am Heart J 121:148-57
12. Pu Y, Jin M. (2005). Study of hydroxysafflower yellow A improves myocardial ischemia. Chin Herbal Med 35:374-475
13. Sano M, Minamino T, Toko H, et al. (2007). p53-Induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 446:444-8
14. Song Y, Zhang L, Qu K, et al. (2005). Hydroxysafflor yellow A promotes vascular endothelial cell proliferation via VEGF/VEGF receptor. J Chin Pharm Sci 14:181-5
15. Tian J, Jang W, Wang Z, et al. (2003). Effects of safflower flavone on local cerebral ischemia and thrombosis formation in rats. Chin Trad Herb Drugs 34:741-3
16. Verdecchia P, Carini G, Circo A, et al.; MAVI (MAssa Ventricolare sinistra nell'Ipertensione) Study Group. (2001). Left ventricular mass and cardiovascular morbidity in essential hypertension: The MAVI study. J Am Coll Cardiol 38:1829-35
17. Wei XB, Liu HQ, Sun X, et al. (2005). Hydroxysafflor yellow A protects rat brains against ischemia-reperfusion injury by antioxidant action. Neurosci Lett 386:58-62
18. Xiao WY. (2006). Investigative progress of safflor yellow. Proc Clin Med J 15:646-9
19. Xu CH, Zhang SF, Ma EM. (2005). Protective effect of safflor yellow A on myocardial ischemical reperfusion injury of rats. Chin J Clin Rehabil 43:93-5
20. Zang B, Jin M, Si N, et al. (2002). Platelet activating factor receptor binding can be antagonized by HSYA. Acta Pharm Sin 37:696-9
21. Zervoudaki A, Economou E, Stefanadis C, et al. (2003). Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment. J Hum Hypertens 17:119-24
22. Zheng WC, Chen DB, Zhang L, et al. (2005). The effects and mechanism of safflor yellow A on myocardial ischemia. Chin Pharmacol Bull 21: 978-80
23. Zhou T, Li S. (2007). Multi-target recognition in intracellular regulation networks. Tsinghua Sci Technol 12:629-37